Open AccessPharmacoepidemiological study of treatment managment in patients with type 2 diabetes mellitus in Omsk
Author(s) -
Ананичева Елена Викторовна,
Ананичева Елена Викторовна,
Skalskiy Sergey Viktorovich,
Скальский Сергей Викторович,
Shukil Ludmila Vladimirovna,
Шукиль Людмила Владимировна,
Петунина Мирослава Валерьевна,
Петунина Мирослава Валерьевна,
Паручикова Светлана Александровна,
Паручикова Светлана Александровна,
Paymanov Ivan Valer'evich,
Пайманов Иван Валерьевич
Publication year - 2016
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl201662125-34
Subject(s) - medicine , glimepiride , metformin , gliclazide , diabetes mellitus , type 2 diabetes , sulfonylurea , defined daily dose , medical prescription , glibenclamide , type 2 diabetes mellitus , blood pressure , cohort , pharmacology , endocrinology
Treatment management strategy for patients with type 2 diabetes mellitus (2DM) includes glycaemic control, blood pressure and lipid metabolism parameters. Pharmacoepidemiological monitoring allows evaluating the compliance of the treatment really provided for 2DM with the present guidelines.Aim.To study the actual implementation of pharmaceuticals control for patientswith type 2 diabetes, residents of the city of Omsk, in 2013—2014.Material and methods. It was a retrospective open cohort study based on the fragment data of the Regional Diabetes Register including 33 187 cases with prescription of oral antidiabetic drugs (OAD), 285 patient cases and OAD consumption and expenses data in 2014. The prescribed daily dose (PDD) was determined. It was assessed the efficiency and effectiveness of antihypertensive and lipid-lowering therapy.Results.In Omsk metformin prevails in OAD take-in that corresponds to the modern Clinical Guidelines. Prescribed daily doses of metformin (PDD) are significantly lower (by 34.71%) than the doses fixed by the WHO Centre. The second frequently prescribed drugs are sulfonylureas with gliclazide MB at the top. PDD of glimepiride and glibenclamide are considerably higher than DDD. DPP-4 medicines are quite often prescribed (up to 10.2% as a part of the combined therapy, including fixed combinations).Conclusion.The efficacy of antihyperglycemic therapy assessed upon achievement of HbA1c individual target in Omsk is 40.5%. Most patients with type 2 diabetes in the studied cohort have had the adequate antihypertensive therapy with reaching a target blood pressure in 75.8% of patients. Statin drugs are prescribed only in 39.3% of cases of dyslipidemia in type 2 diabetes, and only in 32.3% of them the targets of lipid metabolism parameters are achieved.